Hematologic Oncology

Experts in hematology comment on when it’s appropriate to use gilteritinib, particularly as a combination therapy, to treat patients with FLT3-mutated acute myeloid leukemia.

Jessica K. Altman, MD, and Naval G. Daver, MD, discuss what is known in terms of mechanisms of resistance to FLT3 inhibitors used to treat acute myeloid leukemia.

A key opinion leader in diffuse large B-cell lymphoma provides a historical perspective on third-line options for CAR T-cell therapy and shares insights on both clinical trial and real-world data.

Key opinion leaders in hematology-oncology discuss treatment considerations for first-line chemoimmunotherapy in follicular lymphoma and marginal zone lymphoma and when to use maintenance therapy or observation.

A review of treatment options for patients with chronic GVHD who don’t respond to steroid therapy and preliminary findings from the phase 3 REACH3 trial.

An expert in hematology oncology, Amit Patel, BSc, MBBS, PhD, reviews the unmet needs for patients with relapsed/refractory diffuse large B-cell lymphoma.

Defining steroid-refractory acute GVHD, treatment options for patients who don’t respond to steroid therapy, and a review of the REACH2 trial.

Experts in lymphoma provide insight into factors to consider when initiating treatment and emphasize the importance of both clinical judgment and treatment guidelines like the GELF criteria when monitoring patients.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has granted a positive opinion for the approval of oral azacitidine as a maintenance treatment for adult patients with acute myeloid leukemia who had a complete remission or CR with incomplete blood count recovery after induction therapy with or without consolidation treatment, and who are ineligible for or choose to not undergo hematopoietic stem cell transplant

The European Medicines Agency Committee for Medicinal Products for Human Use has recommended to approve venetoclax for use in combination with hypomethylating agents for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.

Stephen M. Ansell, MD, PhD, discusses the role of positron emission tomography scans in patients with Hodgkin lymphoma.

The FDA has granted a priority review designation to SH-111, a sterile injectable therapy, for the treatment of pediatric patients with T-cell leukemia.

Jeffrey Laurence, MD, discusses the role of leptin in the MASP-2 pathway as well as coagulation and complement pathways.

Dr. Pagel discusses the advances that have been made with PI3K inhibitors in lymphoid malignancies, the impact of the FDA approval of umbralisib on the treatment paradigm in follicular lymphoma and marginal zone lymphoma, and ongoing research poised to expand the armamentarium.

The panel reviews therapeutic options for managing transplant-associated thrombotic microangiopathy and the challenges associated with currently existing agents.

Unmet needs and current areas that are being studied in in essential thrombocythemia.

Pankit Vachhani, MD, highlights treatment considerations in low- to high-risk essential thrombocythemia and patients resistant or intolerant to hydroxyurea. 

Naval G. Daver, MD, leads the discussion on the use sorafenib in combination with hypomethylating agents (HMA) for the treatment of relapsed FLT3-mutated AML.

Examining the need to achieve a true CR (complete remission), especially with recent targeted therapies in relapsed/refractory acute myeloid leukemia.

Experts in hematology-oncology share insights on approaching initial treatment and the treatment goals for acute and chronic GVHD.

Experts in hematology-oncology build a discussion on differences in patient presentation and diagnosis of different types of indolent non-Hodgkin lymphomas such as marginal zone lymphoma and follicular lymphoma.

A discussion on the role of prophylactic therapy for patients after transplant as well as available options for GVHD prophylaxis.

Lori A. Leslie, MD, and Anthony Mato, MD, MSCE, discuss the epidemiology, etiology, and risk factors for different types of lymphoma and provide key insights into those classified as indolent non-Hodgkin’s lymphoma.

William Gradishar, MD, discusses the efficacy of pretreatment with intravenous cetirizine in the prevention of infusion reactions in patients with breast cancer and other malignancies.

Health Canada has approved daratumumab injection, a subcutaneous formulation of daratumumab, for use in combination with bortezomib, cyclophosphamide, and dexamethasone in the treatment of patients with newly diagnosed light chain amyloidosis.